Impact of Black Seed Oil on Hemodialysis Patients
Evaluation of the Impact of Black Seed Oil on Hemodialysis Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Evaluation of the effect of black seed oil in hemodialysis patients via:
- Evaluation of serum Endothelin-1 levels
- Evaluation of serum Malondialdehyde (MDA) levels
- Evaluation of serum Total Antioxidant Capacity (TAC) levels
- Evaluation of Quality of Life (QOL)
- Evaluation of fatigue scale
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Cairo, Egypt
- Ain Shams University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥ 20 years old
- Three to four times per week hemodialysis
- Being on hemodialysis for at least 6 months
- Ability and willingness to cooperate in the study
Exclusion Criteria:
- Pregnancy or lactation
- Cigarette smoking or substance/alcohol abuse
- Having active infectious diseases
- Receiving steroidal or nonsteroidal anti-inflammatory drugs
- Using Nigella sativa oil regularly
- Changes in treatment methods (dialysis) or medications during the supplementation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Black Seed Oil
900 mg (as two separate soft gels) twice daily for 8 weeks
|
Dietary supplement
Other Names:
|
|
Placebo Comparator: Placebo
matched placebo capsules
|
placebo capsules same odor, color and size as the drug but without the active ingredient
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
serum Endothelin-1 (ET-1) level
Time Frame: 8 weeks
|
marker of endothelial dysfunction
|
8 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Serum malondialdehyde (MDA) and total antioxidant capacity (TAC)
Time Frame: 8 weeks
|
markers of oxidative stress
|
8 weeks
|
|
Quality of life questionnaire
Time Frame: 4 weeks and 8 weeks
|
using validated Arabic version SF-36 questionnaire
|
4 weeks and 8 weeks
|
|
Fatigue severity
Time Frame: 4 weeks and 8 weeks
|
using the Multidimensional Fatigue Inventory (MFI)
|
4 weeks and 8 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: May A Shawki, PHD, Faculty of pharmacy - Ain Shams University
- Study Director: Areej M Ateya, PHD, Faculty of pharmacy - Ain Shams University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 119 (hhh)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.